AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)

RecruitingNAAges 18 Years - anyAllInstitute of Oncology Ljubljana
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally advanced, inoperable pancreatic cancer. The study aims to determine the response rate after SBRT delivered following initial chemotherapy, as well as time to disease progression and treatment-related toxicity. Patients receive standard first-line chemotherapy and, in the absence of disease progression, undergo ablative SBRT to the primary tumor, followed by continuation of systemic therapy according to clinical practice. The study is conducted in Slovenia, with patient enrollment expanded to additional participating clinical centers following an approved amendment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years and older * Locally advanced, inoperable pancreatic cancer * Treated with first-line systemic chemotherapy followed by stereotactic body radiotherapy (SBRT) at participating centers * Ability to provide written informed consent Exclusion Criteria: * Metastatic pancreatic cancer * Prior systemic therapy for locally advanced pancreatic cancer (one or more previous lines of systemic treatment) * Disease progression after initial chemotherapy prior to SBRT * Any condition that, in the investigator's opinion, would interfere with study participation or evaluation
๐Ÿ’Š

What it tests

  • Ablative Stereotactic Body Radiotherapy (SBRT)
  • Standard First-Line Chemotherapy
๐Ÿ“

Where

1 site
Institute of Oncology Ljubljana
Ljubljana, Slovenia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy